Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 19, 2016HaematologicaOpen Access

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMaria WinqvistKarolinska University HospitalAAAnna AsklidKarolinska University HospitalPAPer AnderssonLinköping University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Winqvist et al. (2016) studied this question.

synapsesocial.com/papers/6a08fc480465d979db9d0bd7https://doi.org/10.3324/haematol.2016.144576
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemia2006 · 42 citations
  2. 2Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study2014 · 137 citations
  3. 3The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy2007 · 98 citations
  4. 4Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study2015 · 8 citations
  5. 5Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry2014 · 402 citations